发明名称 |
BIOMARKERS FOR PREDICTING OUTCOMES OF CANCER THERAPY WITH ERBB3 INHIBITORS |
摘要 |
Methods for predicting a therapeutic response in a patient (e.g., a cancer patient) to ErbB3 inhibitors, and methods of treating a cancer patient with targeted therapies. |
申请公布号 |
US2017101480(A1) |
申请公布日期 |
2017.04.13 |
申请号 |
US201615173219 |
申请日期 |
2016.06.03 |
申请人 |
Merrimack Pharmaceuticals, Inc. |
发明人 |
BURENKOVA Olga;MACBEATH Gavin;NIE Lin;SEVECKA Mark |
分类号 |
C07K16/32;C07K16/30;C12Q1/68 |
主分类号 |
C07K16/32 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating a patient having a heregulin positive (HRG+) cancer with a solid tumor having a ratio of expressed ErbB4 to ErbB3 of less than 1.3, the method comprising: administering a therapeutically effective amount of an anti-ErbB3 antibody to the patient, wherein the anti-ErbB3 antibody comprises CDRH1, CDRH2, and CDRH3 sequences comprising the amino acid sequences set forth in SEQ ID NO:1 (CDRH1), SEQ ID NO:2 (CDRH2), and SEQ ID NO:3 (CDRH3); and CDRL1, CDRL2, and CDRL3 sequences comprising the amino acid sequences set forth in SEQ ID NO:4 (CDRL1), SEQ ID NO:5 (CDRL2), and SEQ ID NO:6 (CDRL3). |
地址 |
Cambridge MA US |